Diabetes, Vol 45, Issue 12 1750-1754, Copyright © 1996 by American Diabetes Association

ARTICLES

Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin

NS Fineberg, SE Fineberg, JH Anderson, MA Birkett, RG Gibson and S Hufferd
Indiana University School of Medicine, Division of Biostatistics, Indianapolis, USA.

Insulin lispro [Lys (B28), Pro (B29) human insulin] is a rapidly absorbed analog that has diminished tendency to self-associate. In four open-label, 1-year-long international randomized trials, we contrasted the immunogenicity of insulin lispro versus regular human insulin (RHI) in patients previously treated with insulin who had IDDM or NIDDM. Using a self-blank subtraction assay, we assessed sera for the presence of insulin-specific antibodies (ISA), insulin lispro-specific antibodies (LSA), and cross-reactive antibodies (CRA). Basal insulin needs were provided either with human ultralente (UL) or NPH insulins. After 2 to 4 weeks of therapy with RHI plus UL or RHI plus NPH, 50% of patients were randomly assigned to begin insulin lispro or continue on RHI. At baseline, few pretreated patients had LSA (0-4%) and approximately 10% had ISA, whereas 41-45% of patients with IDDM and 23-27% of patients with NIDDM had CRA (IDDM vs. NIDDM, P < 0.001). Within studies, no significant differences were noted over time in ISA, LSA, or CRA attributable to the type of short-acting insulin. When data were pooled, inconsistent changes were noted in ISA and LSA (LSA were greater in NIDDM vs. IDDM at baseline, P = 0.001, and ISA were greater in IDDM vs. NIDDM at 6 months, P = 0.007). Significant levels of CRA were more common in IDDM at all times (P < 0.001, P = 0.022, and P = 0.002 at baseline, 6 months, and 12 months, respectively). For patients receiving insulin lispro, no significant changes occurred in antibody status among IDDM and NIDDM patients throughout the study (became positive, remained positive, became negative, or remained negative). IDDM patients were more likely to develop or maintain CRA levels (P = 0.008 vs. NIDDM), whereas antibody levels were comparable among positive individuals. No evidence was noted that insulin lispro differs in immunogenicity from RHI in previously treated IDDM and NIDDM patients.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. E. Fineberg, T. T. Kawabata, D. Finco-Kent, R. J. Fountaine, G. L. Finch, and A. S. Krasner Immunological Responses to Exogenous Insulin Endocr. Rev., October 1, 2007; 28(6): 625 - 652. [Abstract] [Full Text] [PDF]

				L. Jovanovic and D. J. Pettitt Treatment With Insulin and Its Analogs in Pregnancies Complicated by Diabetes Diabetes Care, July 1, 2007; 30(Supplement_2): S220 - S224. [Full Text] [PDF]

				I. B. Hirsch Insulin Analogues N. Engl. J. Med., January 13, 2005; 352(2): 174 - 183. [Full Text] [PDF]

				M. R. Burge and J. D. Carey Vitiligo Associated With Subcutaneous Insulin Lispro Infusion in Type 1 Diabetes Diabetes Care, January 1, 2004; 27(1): 275 - 276. [Full Text] [PDF]

				F. J. Ampudia-Blasco, B. Hasbum, and R. Carmena A New Case Of Lipoatrophy With Lispro Insulin In Insulin Pump Therapy: Is there any insulin preparation free of complications? Diabetes Care, March 1, 2003; 26(3): 953 - 954. [Full Text] [PDF]

				S. E. Fineberg, J. Huang, R. Brunelle, K. S. Gulliya, and J. H. Anderson Jr Effect of Long-Term Exposure to Insulin Lispro on the Induction of Antibody Response in Patients With Type 1 or Type 2 Diabetes Diabetes Care, January 1, 2003; 26(1): 89 - 96. [Abstract] [Full Text] [PDF]

				A. Lindholm, L. B. Jensen, P. D. Home, P. Raskin, B. O. Boehm, and J. Rastam Immune Responses to Insulin Aspart and Biphasic Insulin Aspart in People With Type 1 and Type 2 Diabetes Diabetes Care, May 1, 2002; 25(5): 876 - 882. [Abstract] [Full Text] [PDF]

				L. C. Deeb, J. H. Holcombe, R. Brunelle, S. Zalani, S. Brink, M. Jenner, H. Kitson, K. Perlman, and M. Spencer Insulin Lispro Lowers Postprandial Glucose in Prepubertal Children With Diabetes Pediatrics, November 1, 2001; 108(5): 1175 - 1179. [Abstract] [Full Text] [PDF]

				Z. Vajo, J. Fawcett, and W. C. Duckworth Recombinant DNA Technology in the Treatment of Diabetes: Insulin Analogs Endocr. Rev., October 1, 2001; 22(5): 706 - 717. [Abstract] [Full Text] [PDF]

				M. E. Griffin, A. Feder, and W. V. Tamborlane Lipoatrophy Associated With Lispro Insulin in Insulin Pump Therapy: An old complication, a new cause? Diabetes Care, January 1, 2001; 24(1): 174 - 174. [Full Text]

				Z. Vajo and W. C. Duckworth Genetically Engineered Insulin Analogs: Diabetes in the New Millenium Pharmacol. Rev., March 1, 2000; 52(1): 1 - 10. [Abstract] [Full Text] [PDF]

				{blacktriangledown}Humalog - a new insulin analogue DTB, August 1, 1997; 35(8): 57 - 58. [Abstract] [Full Text] [PDF]

				F. Holleman and J. B.L. Hoekstra Insulin Lispro N. Engl. J. Med., July 17, 1997; 337(3): 176 - 183. [Full Text] [PDF]